PR Newswire - PharmAbcine's Phase 1 Clinical Trial of PMC-403 fo...
Safety Review Committee (SRC) approves single 3mg dose for the third cohort in Phase 1 trial of PMC-403 DAEJEON, South Korea, July 2, 2024 /PRNewswire/ -- PharmAbcine, I...
Read More

ภาษาไทย
English